文献速递其他结缔组织病

系统性硬化症相关间质性肺疾病患者继续使用尼达尼布:SENSCIS-ON 的 3 年数据

Continued nintedanib in patients with systemic sclerosis-associated interstitial lung disease: 3-year data from SENSCIS-ON.
PubMed 文献 · RMD Open · 2025-02-23

SENSCIS-ON 扩展研究评估了开放标签尼达尼布治疗 148 周的不良事件和用力肺活量变化。继续尼达尼布组 197 例,新启用尼达尼布组 247 例。腹泻是最常见不良事件。第 148 周 FVC 平均变化继续组为 -189.1 mL,新启用组为 -126.4 mL。结论认为安全性特征与 SENSCIS 一致,FVC 变化支持尼达尼布持续减缓肺功能下降的效应,但显示 SSc-ILD 持续进展。

要点

  • 继续尼达尼布组 197 例,新启用尼达尼布组 247 例(其中 231 例来自 SENSCIS)。
  • 腹泻是最常见不良事件,继续组 152 例(77.2%),新启用组 183 例(74.1%)。
  • 第 148 周 FVC 平均变化继续组 -189.1 mL,新启用组 -126.4 mL。

核心结论

  • SENSCIS-ON 中尼达尼布治疗 148 周的安全性特征与 SENSCIS 报告的一致。
  • SENSCIS 和 SENSCIS-ON 期间的 FVC 变化支持尼达尼布持续减缓肺功能下降的效应,但显示 SSc-ILD 持续进展。

研究设计与样本

  • SENSCIS-ON 是 SENSCIS 试验的扩展研究,评估开放标签尼达尼布治疗 148 周的不良事件和 FVC 变化。
  • 继续尼达尼布组为在 SENSCIS 中接受尼达尼布并在 SENSCIS-ON 中继续尼达尼布的患者,共 197 例。
  • 新启用尼达尼布组为在 SENSCIS 中接受安慰剂或在药物相互作用研究中接受尼达尼布≤28 天后在 SENSCIS-ON 中接受尼达尼布的患者,共 247 例(其中 231 例来自 SENSCIS)。

主要发现

  • 腹泻是最常见不良事件,继续尼达尼布组 152 例(77.2%),新启用尼达尼布组 183 例(74.1%)。
  • 继续尼达尼布组 53 例(26.9%)和新启用尼达尼布组 148 例(59.9%)发生至少 1 次剂量减少。
  • 继续尼达尼布组 72 例(36.5%)和新启用尼达尼布组 131 例(53.0%)发生至少 1 次治疗中断。
  • 继续尼达尼布组 29 例(14.7%)和新启用尼达尼布组 72 例(29.1%)发生导致治疗停药的不良事件。
  • 第 148 周 FVC 平均(SE)变化继续尼达尼布组为 -189.1(29.5)mL,新启用尼达尼布组为 -126.4(26.4)mL。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We assessed adverse events and changes in forced vital capacity (FVC) in patients treated with open-label nintedanib over 148 weeks of SENSCIS-ON, the extension of the SENSCIS trial. METHODS: Adverse events and changes in FVC over 148 weeks of SENSCIS-ON were assessed in patients who received nintedanib in SENSCIS and continued nintedanib in SENSCIS-ON ('continued nintedanib' group) and in patients who received placebo in SENSCIS or received nintedanib for ≤28 days in a drug-drug interaction study and then received nintedanib in SENSCIS-ON ('initiated nintedanib' group). RESULTS: The continued nintedanib group comprised 197 patients, and the initiated nintedanib group comprised 247 patients (231 from SENSCIS). Diarrhoea was the most frequent adverse event, reported in 152 (77.2%) and 183 (74.1%) patients in the continued nintedanib and initiated nintedanib groups, respectively. Among patients in the continued and initiated nintedanib groups, respectively, 53 (26.9%) and 148 (59.9%) had ≥1 dose reduction, 72 (36.5%) and 131 (53.0%) had ≥1 treatment interruption and 29 (14.7%) and 72 (29.1%) had adverse events that led to treatment discontinuation. Mean (SE) changes in FVC (mL) at week 148 were -189.1 (29.5) in the continued nintedanib group and -126.4 (26.4) in the initiated nintedanib group. CONCLUSION: The safety profile of nintedanib over 148 weeks of SENSCIS-ON was consistent with that reported in SENSCIS. Changes in FVC during SENSCIS and SENSCIS-ON supported a continued effect of nintedanib on slowing the decline in lung function, but showed continued progression of SSc-ILD.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Allanore Y, Vonk MC, Distler O, et al. Continued nintedanib in patients with systemic sclerosis-associated interstitial lung disease: 3-year data from SENSCIS-ON. RMD Open. 2025. PMID: 39988350. doi:10.1136/rmdopen-2024-005086

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。